NTLA – intellia therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares [Yahoo! Finance]
Fred Cohen Buys 303% More Intellia Therapeutics Shares [Yahoo! Finance]
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Intellia Stock Declines Around 55% in 3 Months: Here's Why [Yahoo! Finance]
Form 8-K Intellia Therapeutics, For: Jan 09
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: LEONARD JOHN M
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Lebwohl David
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Schultes Birgit C
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: BASTA JAMES
Top News Decliners
3/13 Form 8-K Intellia Therapeutics, For: Mar 12 -17.6%
6/10 Intellia Therapeutics Inc (NASDAQ: NTLA) is now covered by analysts at Roth Capital. They set a "neutral" rating and a $16.00 price target on the stock. -10.3%
4/1 Intellia Therapeutics Inc (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $57.50 price target on the stock. -8.8%
8/26 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.2%
4/28 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. -7.8%
9/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was given a new $57.50 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. -7.7%
5/7 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
4/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.6%
4/21 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -7.5%
2/14 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. -7.3%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.